Advertisement
U.S. markets closed
  • S&P Futures

    5,304.25
    -4.00 (-0.08%)
     
  • Dow Futures

    40,140.00
    -36.00 (-0.09%)
     
  • Nasdaq Futures

    18,465.00
    -38.75 (-0.21%)
     
  • Russell 2000 Futures

    2,145.20
    +6.80 (+0.32%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0786
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • Vix

    13.01
    +0.23 (+1.80%)
     
  • GBP/USD

    1.2629
    +0.0007 (+0.06%)
     
  • USD/JPY

    151.3360
    -0.0360 (-0.02%)
     
  • Bitcoin USD

    70,774.05
    +1,221.88 (+1.76%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,316.75
    +148.68 (+0.37%)
     

Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches

Before Tuesday, 90 percent of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) analysts were buying the stock. But one analyst has diluted the decisive bullishness with rare ambivalence.

The Rating

Goldman Sachs analyst Dana Flanders initiated coverage on Alder with a Neutral rating and $17 price target.

The Thesis

The rating reflects ambiguity around commercial questions for IV eptinezumab, a calcitonin gene-related peptide monoclonal antibody inhibitor that Flanders said he expects to launch in the second half of 2019. (See the analyst's track record here.)

The analyst considers the significant and underserved migraine market a $5-billion opportunity, but also a highly competitive one. Amgen, Inc. (NASDAQ: AMGN), Eli Lilly And Co (NYSE: LLY) and Teva Pharmaceuticals Industries Ltd (ADR) ADR (NYSE: TEVA) are developing competing mAbs.

Goldman Sachs forecast five-year sales of around $650 million.

“We spoke with a neurologist at a leading academic headache center, who did not view current data supporting meaningful differentiation across CGRP agents,” Flanders said in a note. “However, she noted unmet need for new migraine therapies, was positive on overall CGRP efficacy and expected 25-percent to 33-percent uptake across eligible patients at her institution in four to five years.”

The estimates assume positive reimbursement conditions and the establishment of the long-term safety of the therapy.

Price Action

Alder Pharma shares were down 2 percent at the time of publication Tuesday.

Related Links:

The Week Ahead In Biotech: PDUFA Dates, IPOs And More

The Size Effect Is Working With Health Care ETFs

Latest Ratings for ALDR

Apr 2018

Goldman Sachs

Initiates Coverage On

Neutral

Oct 2017

Canaccord Genuity

Initiates Coverage On

Buy

Sep 2017

Cowen & Co.

Initiates Coverage On

Outperform

View More Analyst Ratings for ALDR
View the Latest Analyst Ratings

See more from Benzinga

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement